NCT05870670View on ClinicalTrials.gov

A Research Study of a New Medicine NNC0519-0130 in Japanese and Non-Japanese Men

PHASE1CompletedINTERVENTIONAL

Enrollment

22

Participants

Timeline

Start Date

May 15, 2023

Primary Completion Date

October 7, 2023

Study Completion Date

October 16, 2023

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

NNC0519-0130

Administered subcutaneously.

DRUG

Placebo

Administered subcutaneously.

Trial Locations (1)

130-0004

SOUSEIKAI Sumida Hospital, Tokyo

Sponsors

Lead Sponsor

Novo Nordisk A/S

All Listed Sponsors

lead

Novo Nordisk A/S

INDUSTRY